The approved GLP-1R agonists are peptide-based molecules that mimic the action of endogenous GLP-1, enhancing glucose-dependent insulin secretion, suppressing glucagon release, delaying gastric emptying, and thereby improving glycemic control in patients with type 2 diabetes. Here, GCG is linked to type 2 diabetes mellitus.